Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LifeCell

This article was originally published in The Gray Sheet

Executive Summary

Nets approximately $5 mil. from the private sale of 263,250 units, each consisting of one share of series A convertible preferred stock and one warrant to purchase one share of common stock. The Woodlands, Texas-based firm says the funds will pay for company operations until mid-1996 and will enable an acceleration of sales and marketing efforts for its AlloDerm universal dermal tissue graft, introduced last December. "Significant investors" in the offering included Medtronic and Allstate Insurance Company, LifeCell says. Medtronic and LifeCell entered a pact earlier this year to co-develop a tissue heart valve ("The Gray Sheet" March 7, I&W-4).
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel